
BioLife Solutions (BLFS) Stock Forecast & Price Target
BioLife Solutions (BLFS) Analyst Ratings
Bulls say
BioLife Solutions is well-positioned for growth in the cell and gene therapy industry, driven by their innovative biopreservation products and increasing use in clinical trials. The company's strong financial performance, including a 21% year-over-year increase in revenue and 30% increase in adjusted EBITDA, bodes well for the future of the company. The pending acquisition by Repligen is expected to bring additional synergies and accretion to the company, further enhancing its growth potential and solidifying its position in the market.
Bears say
BioLife Solutions is set to be acquired by Repligen, which management states was a logical outcome following years of portfolio simplification and refocusing around the company's core biopreservation media franchise. While the company's position in biopreservation and exposure to cell and gene therapy growth is positive, the acquisition has largely captured the near-term value creation opportunity, leading to a new Hold rating and price target of $31.
This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.
BioLife Solutions (BLFS) Analyst Forecast & Price Prediction
Start investing in BioLife Solutions (BLFS)
Order type
Buy in
Order amount
Est. shares
0 shares